• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Insul-Inn

    6/23/22 8:00:00 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVO alert in real time by email

    Newly renovated medical centre designed to provide youth living with type 1 diabetes with on-site care

    HUNTSVILLE, ON, June 23, 2022 /CNW/ - Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment.

    Novo Nordisk Canada Inc. (CNW Group/Novo Nordisk Canada Inc.)

    The old medical centre is estimated to have been built in 1954 and has undergone various renovations over the years. In 2021, Diabetes Canada announced the on-site medical centre at Camp Huronda – the Insul-Inn – would be rebuilt to provide a new space where medical staff can continue to guide and support youth learning to manage their diabetes, plus provide campers with the on-site care they need. On June 26th, Camp Huronda staff and partners will unveil the newly built Insul-Inn, and welcome families back to the highly anticipated re-opening of the summer camp season.

    For young people and their families affected by type 1 diabetes, Camp Huronda provides a sense of community, and a place to gather and share mutual experiences with one another. Diabetes Canada is proud to provide an environment where campers can spend time with other children living with diabetes, while increasing their independence in managing their health, with the support of trained medical staff.

    "Diabetes Canada could not be more excited to welcome the D-Camps community back to camp," says Laura Syron, President and CEO, Diabetes Canada. "After two years of virtual camp, campers can finally get back to doing what they love at their home-away-from-home. The opening of the newly constructed Insul-Inn is significant – it gives our medical staff a new home, where they can continue to care for our campers so they can enjoy the camping experience to the fullest."

    At Camp Huronda, shared experiences exist that make for rich and authentic connections. Not only do Camp Huronda's on-site medical professionals provide specialized healthcare to campers, many also live with type 1 diabetes. This reinforces a sense of belonging and encourages campers to aspire to a "no limits" mentality.

    "Camp Huronda helped me learn to manage my diabetes and gave me an incredible camp experience," says Taylor Hall, former Camp Huronda camper and current camp counsellor. "I have made lifelong friends with people who understand what it's like to live with type 1 diabetes. Going back to camp this summer, in-person, and now as part of the staff could not be more exciting."

    "Just like the campers and families, the medical team is thrilled to be returning to Camp Huronda this summer," says Dr. Donna Goldenberg, Paediatrician, Trillium Health Partners – Credit Valley Hospital and Hospital for Sick Children ER Physician. "Providing children with the best camp experience possible is always our objective, and we are excited to continue caring for our campers at our newly renovated on-site medical centre."

    The Camp Huronda medical centre rebuild was made possible through support from Novo Nordisk Canada and demonstrates their continued commitment to the type 1 diabetes community in Canada.

    "We know the important role Camp Huronda plays in the lives of those affected by type 1 diabetes, and it's amazing to have children safely back at camp," says Béatrice Clerc, President, Novo Nordisk Canada. "Novo Nordisk is proud to give back in a meaningful way and contribute to this milestone that will provide children with an incredible camp experience."

    About D-Camps

    Diabetes Canada's camping tradition began in 1953 in Eastern Ontario. Since that time, the camp program has grown extensively, and currently operates nine overnight camp programs across Canada plus numerous year-round programs. Learn more at diabetes.ca/d-camps. 

    About Diabetes Canada

    A world free of the effects of diabetes is our vision. That's why we're working together to improve the quality of life of people living with diabetes. We're sharing knowledge and creating connections for individuals and the health-care professionals who care for them; advocating through public policy; and funding research to improve treatments and find a cure to end diabetes. For more information, visit diabetes.ca or call 1-800-BANTING (226-8464).

    About Novo Nordisk

    Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

    To learn more about D-Camps, visit dcamps.ca or call 1-800-BANTING (226-8464).

    Camp Huronda welcomes back campers for a long-awaited reopening and unveils the new Insul-Inn (CNW Group/Novo Nordisk Canada Inc.)

    Diabetes Canada (CNW Group/Novo Nordisk Canada Inc.)

    D Camps (CNW Group/Novo Nordisk Canada Inc.)

    SOURCE Novo Nordisk Canada Inc.

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/23/c6449.html

    Get the next $NVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVO

    DatePrice TargetRatingAnalyst
    3/26/2026Peer Perform
    Wolfe Research
    3/18/2026Underperform
    Bernstein
    3/18/2026$175.00Outperform
    Bernstein
    3/10/2026$42.00Buy → Hold
    TD Cowen
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    3/2/2026$41.00Buy → Neutral
    Goldman
    2/24/2026Buy → Hold
    Kepler
    2/24/2026Overweight → Neutral
    Analyst
    More analyst ratings

    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Novo Nordisk A/S

    Wolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform

    3/18/26 3:58:44 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S with a new price target

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00

    3/18/26 1:57:24 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVO
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    4/13/26 7:52:08 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    4/7/26 7:28:44 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/30/26 9:05:01 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile

    Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.

    3/19/26 12:04:00 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

    Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1Starting dose of Wegovy® pill (1.5 mg) available today for only $149 per month (or $5 per day) via easy to access self-pay offerWegovy® pill now broadly available through 70,000+ US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare® Pharmacy, GoodRx and morePLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026 /PRNewswire/ -- Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a p

    1/5/26 8:00:00 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The End of Shots? 5 Biotech Stocks Rethinking Diabetes

    Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching record valuations as major pharmaceutical companies race to secure curative platforms over symptom-management franchises[2]. This pivot toward functional cures rather than chronic insulin dependence is defining the strategic roadmaps of Avant Technologies, Inc. (OTCQB:AVAI), Novo Nordisk A/S (NYSE:NVO), Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), Viking Therapeutics, Inc. (NASDAQ:VKTX), and Tandem Diabetes C

    12/31/25 8:07:00 AM ET
    $ELDN
    $NVO
    $TNDM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $NVO
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    EXL Announces Appointment of Andreas Fibig to Board of Directors

    NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo

    1/12/23 4:01:00 PM ET
    $EXLS
    $IFF
    $NVO
    Real Estate
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations

    Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

    12/1/20 4:30:00 PM ET
    $LLY
    $DRNA
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $NVO
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Metsera, Inc./

    In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

    Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Unsolicited Proposal from Novo Nordisk

    Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments to Existing Transaction Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) ("Novo Nordisk") to acquire Metsera (th

    10/30/25 7:07:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care